BHC: Bausch Health Companies Inc. - Summary | Jitta

Bausch Health Companies Inc.

NYSE:BHC

Price
$5.72
Loss Chance
43.2%
5.04JITTA SCORE
76.39%Under Jitta Line
Jitta Ranking
36 / 719
385 / 4,228
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (67)
Recent Business Performance (73)
Financial Strength (60)
Return to Shareholders (5)
Competitive Advantage (53)
Jitta Signs
Revenue and EarningConsistent
Operating MarginConsistent
Debt LevelVery High Long Term Debt
Recent Business PerformanceEarning decline 39694.80% in the last quarter (yoy)
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.04
76.39%
3.14
94.26%
3.07
427.75%
Pharmaceuticals
4.91
50.34%
5.32
90.39%
4.55
18.49%
COMPANY DESCRIPTION
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.